After SVB Securities and Citigroup gave Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein maintained a Buy rating on Amylyx Pharmaceuticals Inc today and set a price target of $35.00. The company’s shares closed last Friday at $11.63.
According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of -22.5% and a 27.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Global Blood Therapeutics, and Deciphera Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $25.33 average price target, a 90.5% upside from current levels. In a report issued on May 25, Citigroup also initiated coverage with a Buy rating on the stock with a $21.00 price target.
The company has a one-year high of $33.41 and a one-year low of $6.51. Currently, Amylyx Pharmaceuticals Inc has an average volume of 723.3K.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMLX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Read More on AMLX: